Effects of growth hormone treatment on growth and body composition in Prader-Willi syndrome: a preliminary report. The Swedish National Growth Hormone Advisory Group.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

A controlled, randomized study was conducted to assess the effect of growth hormone (GH) treatment on growth, body composition and behaviour in prepubertal children (3-12 years of age) with Prader-Willi syndrome.

Why It Was Studied

All patients had low 24-hour levels of GH and insulin-like growth factor I before GH treatment.

When GH treatment was stopped, height velocity declined dramatically.

Who Took Part

According to the abstract, 15 patients were involved.

By PubMed's age tags, the people studied were young children and children, men only.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

What Was Measured

All patients had low 24-hour levels of GH and insulin-like growth factor I before GH treatment.

Topics PubMed links to this paper include Body Height, Child Behavior, Growth, Human Growth Hormone and Prader-Willi Syndrome.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 15 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1997 (Acta paediatrica (Oslo, Norway : 1992). Supplement), a journal based in Norway.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.